Stockreport

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line [Yahoo! Finance...

Legend Biotech Corporation - American Depositary Shares  (LEGN) 
PDF Late-breaking data featured in an oral presentation at the 21 st International Myeloma Society Annual Meeting SOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Legen [Read more]